On June 30, 2026, Color Health — the virtual cancer clinic that serves employer, health-plan, and public-sector populations — announced it is offering the Onclarity HPV Self-Collection Kit through its platform, an FDA-cleared at-home swab test that detects 14 high-risk HPV genotypes and individually identifies six specific high-risk strains. The kit is supplied via a partnership in the Waters Corporation diagnostics orbit (Waters Advanced Diagnostics / SNT Biotech), and Color wraps it in oncologist-led clinical follow-up rather than selling it as a standalone test.

Why It Matters

Cervical-cancer screening sits squarely at the intersection of sexual and reproductive health, and at-home HPV self-collection is one of the highest-leverage femtech tools to close screening gaps — particularly for people who avoid speculum-based exams or lack easy clinic access. Embedding the swab inside an employer- and payer-facing virtual clinic (rather than a DTC kit) is the strategically interesting part: it routes the test through covered benefits and guarantees clinical follow-up, addressing the long-standing critique that at-home tests too often dead-end at a positive result with no care pathway. For the broader sexual-health diagnostics market, it's another sign that the future of intimate-health testing is self-collection at home plus a coordinated clinical wrapper.

The differentiator is extended genotyping. Traditional cervical-cancer screening clumps high-risk HPV strains into one or two broad groups; Onclarity isolates individual genotypes beyond the familiar HPV 16, 18, and 45, enabling more precise risk stratification and tailored follow-up. "Despite cervical cancer being preventable, a woman dies from the disease every 90 seconds," said Dr. Jeff Andrews, VP of medical sciences at Waters Advanced Diagnostics, arguing that at-home self-collection removes the access barriers — scheduling, discomfort, clinic distance — that keep many people from getting screened at all.

Color says its model pairs the test with follow-up through its ASCO-certified Virtual Cancer Clinic, reporting a 77% increase in screening adherence, 100% clinical follow-up for every abnormal result, and a 66% reduction in time from abnormal result to cancer diagnosis. The launch lands the same week SNT Biotech and Waters publicized the broader push to bring comprehensive FDA-cleared at-home HPV screening to US patients.

Sources

Update — 2026-06-30

Initial entry — story first created.